Showing 1341-1350 of 2166 results for "".
Stratifying Glaucoma Risk and Stage
https://modernod.com/mod-issues/2023-jan-feb/stratifying-glaucoma-risk-and-stage/38550/Pivotal studies offer guidance on clinical decisions.Preventing Contact Lens Dropout and Complications
https://modernod.com/mod-issues/mayjune-2025-supplement/preventing-contact-lens-dropout-and-complications/38998/Practical approaches to prevent common issues related to lens wear.Refractive Solutions for Every Age
https://modernod.com/topics/myopia/refractive-solutions-for-every-age/39019/An inventory of corrective options for patients from childhood to retirement.Putting the “V” in Vitreomacular Traction
https://modernod.com/topics/retina/putting-the-v-in-vitreomacular-traction/39021/Some cases resolve spontaneously; others require surgical intervention.Overcoming Treatment Plateaus in Chronic DME
https://evolvemeded.com/specialty/retina/Overcoming-Treatment-Plateaus-in-Chronic-DME-2506/33190/Learn about a patient with a 9-year history of injections for treatment of retinal disease and the final approach resulting in positive outcomes.Glaucoma Pipeline: A View Into Ongoing Innovation
https://cdn.modernod.com/uploads/mod/radio/segment/pdfs/0122GT_Pipeline%20Poster%20Final.pdfPricing Strategies for Toric Contact Lenses
https://modernod.com/business-matters/drive-your-practice-forward-with-new-toric-technology-direction/pricing-strategies-for-toric-contact-lenses/38911/Advances in comfort, fit, and performance mean these lenses now offer greater value.Next-Level AMD Management
https://modernod.com/topics/retina/next-level-amd-management/48720/Advances have the potential to improve care and help patients maintain usable vision.A Collaborative Approach to Geographic Atrophy Management
https://modernod.com/topics/retina/a-collaborative-approach-to-geographic-atrophy-management/48721/How optometrists and ophthalmologists can comanage these patients.Tryptyr Now Available in US
https://modernod.com/podcasts/eyewire-news-the-podcast/tryptyr-now-available-in-us/37095/Alcon launches its recently approved dry eye drug Tryptyr; a potential $1 billion deal is made to advance extended-release therapies for eye diseases; and two companies with late-stage AMD drug candidates complete phase 3 enrollment. Learn more about your ad choices. Visit megaphone.fm/adchoices